← Leaderboards
Brahm H. Segal
Roswell Park Cancer Institute Corp
$5,088,454
Attributed
$8,057,661
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $821.8K · FY2009–25$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,057,661 · 3
By mechanism
R01$8,057,661 · 3
Top collaborators
- Kirsten B Moysich6 shared
- Emese Zsiros4 shared
Most similar at Roswell Park Cancer Institute Corp
Same institution · by research overlap
- Scott I. Abrams$11,133,748
- Kathryn L Lunetta$12,857,453
- Leigh Ellis$3,518,676
- Xiang-Yang Wang$11,998,946
- Christine B. Ambrosone$40,409,261
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorInflammatoryNeutrophilMalignant NeoplasmsPathway InteractionsSignal TransductionAscitesEpithelial Ovarian CancerTumor MicroenvironmentTherapeutic TargetTumor ProgressionNeutrophil InfiltrationMouse ModelMalignant Neoplasm Of OvaryResponseFoundationsImmunotherapyInfectionMicrobialHost DefenseInflammationMitochondriaBloodApoptosis
Grant awards (15)
Targeting complement to enhance antitumor immunity and control malignant effusions in patients with recurrent epithelial ovarian cancer$642,760
R01 · FY2025 · CA
Targeting complement to enhance antitumor immunity and control malignant effusions in patients with recurrent epithelial ovarian cancer$618,854
R01 · FY2024 · CA
Targeting complement to enhance antitumor immunity and control malignant effusions in patients with recurrent epithelial ovarian cancer$645,738
R01 · FY2023 · CA
Targeting complement to enhance antitumor immunity and control malignant effusions in patients with recurrent epithelial ovarian cancer$693,903
R01 · FY2022 · CA
Novel immunological biomarkers ovarian cancer prognosis$613,871
R01 · FY2019 · CA · contact PI
A CRISPR-based platform for testing neutrophil responses in the ovarian cancer microenvironment$207,918
R01 · FY2019 · CA · contact PI
Novel immunological biomarkers ovarian cancer prognosis$632,858
R01 · FY2018 · CA · contact PI
Novel immunological biomarkers ovarian cancer prognosis$646,389
R01 · FY2017 · CA · contact PI
Novel immunological biomarkers ovarian cancer prognosis$646,389
R01 · FY2016 · CA · contact PI
Novel immunological biomarkers ovarian cancer prognosis$589,735
R01 · FY2015 · CA · contact PI
Role of NADPH Oxidase in Regulating Inflammation$410,597
R01 · FY2013 · AI · contact PI
Role of NADPH Oxidase in Regulating Inflammation$431,525
R01 · FY2012 · AI · contact PI
Role of NADPH Oxidase in Regulating Inflammation$426,399
R01 · FY2011 · AI · contact PI
Role of NADPH Oxidase in Regulating Inflammation$425,678
R01 · FY2010 · AI · contact PI
Role of NADPH Oxidase in Regulating Inflammation$425,047
R01 · FY2009 · AI · contact PI